Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gold, M.
Right arrow Articles by Thompson, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gold, M.
Right arrow Articles by Thompson, B.

Chest, Vol 100, 1215-1218, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Esmolol and ventilatory function in cardiac patients with COPD

MR Gold, GW Dec, D Cocca-Spofford and BT Thompson
Cardiac Unit, Massachusetts General Hospital, Boston.

To assess the effects of acute cardioselective beta blockade on ventilatory function in patients with COPD and active cardiac disorders, 50 patients were studied during intravenous infusion of esmolol. All patients had an obstructive ventilatory component on baseline pulmonary function testing, and 58 percent had a significant bronchodilator response to inhaled albuterol. Esmolol infusion (8 to 24 mg/min) produced large decreases in heart rate (84 +/- 2 to 69 +/- 2 beats/min, p less than 0.01) and SBP (124 +/- 3 to 106 +/- 3 mm Hg, p less than 0.01). Despite this marked hemodynamic response, there was no significant group effect of beta blockade on pulmonary function. No patient experienced dyspnea or wheezing with acute esmolol infusion; however, three patients (6 percent) developed asymptomatic decreases of FEV1. It is concluded that acute beta blockade with esmolol can be achieved in patients with COPD and cardiac disorders with little risk of bronchospasm.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
M. R Andrus, K. P Holloway, and D. B Clark
Use of {beta}-Blockers in Patients with COPD
Ann. Pharmacother., January 1, 2004; 38(1): 142 - 145.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. Guyatt
A 75-Year-Old Man With Congestive Heart Failure
JAMA, June 23, 1999; 281(24): 2321 - 2328.
[Full Text] [PDF]

Home page
 NEJMHome page
S. S. Gottlieb, R. J. McCarter, and R. A. Vogel
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
N. Engl. J. Med., August 20, 1998; 339(8): 489 - 497.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. J. Rashba, M. Cooklin, K. MacMurdy, N. Kavesh, M. Kirk, S. Sarang, R. W. Peters, S. R. Shorofsky, and M. R. Gold
Effects of Selective Autonomic Blockade on T-Wave Alternans in Humans
Circulation, February 19, 2002; 105(7): 837 - 842.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.